How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02.

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ) , Skyworks Solutions (SWKS) , Madrigal Pharmaceuticals (MDGL) , Noble (NE) , ACADIA Pharmaceuticals (ACAD) , Gilead Sciences (GILD) , Eiger BioPharmaceuticals (EIGR) , Iconix Brand Group (ICON) , Celldex Therapeutics (CLDX) and Edap Tms (EDAP) .

NASDAQ:ACHN

Achillion Pharmaceuticals (ACHN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ACHN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.79
▼
$0.80
50-Day Range: $6.76
▼
$6.76
52-Week Range: $2.06
▼
$7.01

Volume: 1,910 shs
Average Volume: 8.44 million shs
Market Capitalization: $110.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Achillion Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Achillion Pharmaceuticals Stock (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

ACHN Stock News Headlines

March 30, 2024 | benzinga.com

Kim P. Kamdar's Net Worth

May 20, 2023 | fool.com

Lexicon Pharmaceuticals (NASDAQ: LXRX)

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 19, 2023 | thestreet.com

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

September 18, 2022 | investing.com

ACHN_old Historical Data

January 13, 2022 | thestreet.com

Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today

January 12, 2022 | thestreet.com

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

See More Headlines

Receive ACHN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2019
Today: 4/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ACHN
CUSIP: 00448Q20
CIK: 1070336
Web: www.achillion.com
Phone: 203-624-7000
Fax: N/A
Employees: 56
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.95%
Return on Assets: -29.09%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 8.96
Quick Ratio: 8.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.92 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 140,047,000
Free Float: N/A
Market Cap: $110.80 million
Optionable: Optionable
Beta: 1.59

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Joseph Truitt (Age 54)
Pres, CEO & Director
Ms. Martha E. Manning (Age 64)
Exec. VP, Gen. Counsel & Corp. Sec.
Mr. Brian R. Di Donato (Age 52)
CFO, SVP & Treasurer
Mr. Paul Firuta (Age 53)
Exec. VP & COO
Dr. Kevin P. Malobisky
Sr. VP of Regulatory Affairs, Quality & Compliance

Key Competitors

View All Competitors

ACHN Stock Analysis - Frequently Asked Questions

How were Achillion Pharmaceuticals' earnings last quarter?: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02.
What other stocks do shareholders of Achillion Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX) and Edap Tms (EDAP).

This page (NASDAQ:ACHN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Achillion Pharmaceuticals (ACHN) Stock Price, News & Analysis

About Achillion Pharmaceuticals Stock (NASDAQ:ACHN)

ACHN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ACHN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info